Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
P/E ratio for Cogent Biosciences, Inc. (COGT)
P/E ratio as of 2023: -2.43
According to Cogent Biosciences, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.43. At the end of 2022 the company had a P/E ratio of -5.12.
P/E ratio history for Cogent Biosciences, Inc. from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -2.43 |
| 2022 | -5.12 |
| 2021 | -4.63 |
| 2020 | -1.87 |
| 2019 | -0.72 |
| 2018 | -3.17 |
| 2017 | -3.02 |
| 2016 | -3.36 |
| 2015 | -9.24 |